SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-195289
Filing Date
2023-07-27
Accepted
2023-07-27 07:01:53
Documents
14
Period of Report
2023-07-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d473407d8k.htm   iXBRL 8-K 32023
2 EX-99.1 d473407dex991.htm EX-99.1 12348
6 GRAPHIC g473407img1.jpg GRAPHIC 1861
  Complete submission text file 0001193125-23-195289.txt   179318

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA agle-20230727.xsd EX-101.SCH 2844
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE agle-20230727_lab.xml EX-101.LAB 18757
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE agle-20230727_pre.xml EX-101.PRE 11706
8 EXTRACTED XBRL INSTANCE DOCUMENT d473407d8k_htm.xml XML 3533
Mailing Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT STREET BUILDING 17, SUITE 102B WALTHAM MA 02453 6176515940
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 231115242
SIC: 2834 Pharmaceutical Preparations